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Patients (or Materials) and Methods: Patients treated with DRV for 
HIV infection were enrolled in this study. Efficacy of drug therapy 
was evaluated by relative change of copy number of HIV in blood, 
and the blood samples were taken when the relative copy number of 
< 200 copies/mL. The concentrations of DRV in plasma and PBMC 
were analyzed using HPLC-fluorescence detection method. Then, in 
vitro uptake study using human leukemia cell line, MOLT-4, was 
performed. The intracellular concentrations of DRV were measured 
after exposure to DRV (3.0 μ g/mL in medium) or the combination 
of DRV and ritnavir (RTV) (3.0 and 1.0 μ g/mL in medium, respec-
tively) for 2 hours.
Results: The effective concentrations of DRV in plasma showed 
great variation of 0.88 to 5.57 μ g/mL, while the concentrations 
in PBMC were maintained within a relatively-narrow range 12.9–
28.7ng/106 cells. In in vitro study, RTV, a P-gp inhibitor, significantly 
increase the intracellular concentration of DRV (10.0 vs 15.9 ng/106 
cells).
Conclusion: Our results suggested that the concentration of DRV 
in PBMC could be better indicator for clinical efficacy of DRV com-
pared with that in plasma. In in vitro study, we found that RTV could 
promote the intracellular accumulation of DRV, and it was thought 
to be due to the P-gp inhibitory activity of RTV. Those results mean 
that coadministration of RTV have possibility to increase intracel-
lular concentration of DRV and result to sufficient clinical efficacy of 
DRV regardless the concentration of DRV in plasma.
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Introduction: Triazole antifungal agent voriconazole (VRCZ) 
has a nonlinear pharmacokinetics. VRCZ is extensively metabo-
lized hepatically to major inactive metabolites VRCZ N-oxide 
(VNO). Few clinical reports revealed the influence of VNO on the 
metabolic process of VRCZ. The present study aimed to evaluate 
metabolic process of VRCZ in patients taking plasma concentra-
tion of VNO.
Patients (or Materials) and Methods: Fifty-eight Japanese patients 
receiving oral or intravenous VRCZ for prophylaxis or fungal infec-
tions at Hamamatsu University Hospital were included in the study. 
Predose plasma concentrations of VRCZ and VNO were moni-
tored at day 5 or later. The relationships between plasma exposure 
parameters of VRCZ and VNO were evaluated. CYP2C19 genetic 
polymorphism (G636A and G681A on exon 4 and exon 5) were 
determined using PCR-RFLP method for assessing the influence of 
major metabolic enzyme of VRCZ.
Results: A large interindividual variation was observed in the plasma 
concentrations of VRCZ and VNO. Dose-normalized VRCZ con-
centration had a strong correlation with VRCZ concentration and a 
straight line passing through nearby the origin of the coordinates was 
obtained. No significant correlation between the plasma concentra-
tions of VRCZ and VNO was observed. Plasma concentration ratio 
of VRCZ to VNO (VRCZ/VNO) was strongly correlated with VRCZ 
concentration. No significant difference was observed in the plasma 
concentrations of VRCZ and VNO and VRCZ/VNO between the 
CYP2C19 genotypes.
Conclusion: Metabolic process of VRCZ to VNO is saturable in 
clinical dose range. Our findings indicated that nonlinear pharma-
cokinetics of VRCZ depends on its metabolic saturation
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Introduction: Retigabine (RTG)/ezogabine, N-[2-amino-4(4-
fluorobenzylamino)-phenyl] carbamic acid ethyl ester, is a novel 
antiepileptic compound. In 2011, RTG was approved by the FDA 
and European Commission as adjunctive treatment for partial onset 
seizures in adults aged ≥ 18 years. The global pivotal studies did not 
include Asian countries. The purpose of this study was to character-
ize the pharmacokinetics (PK) of single 50, 100, 200, and 400-mg 
doses of RTG and N-acetyl metabolites of RTG (NAMR) in healthy 
Taiwanese subjects.
Patients (or Materials) and Methods: Sixteen subjects were rand-
omized to the study (ANE116798, NCT01462669), which comprised 
a screening visit, 4 treatment periods, and a follow-up visit. The fol-
lowing PK parameters were determined for RTG and NAMR: Cmax, 
AUC0-inf, Tmax, and t½. Safety and tolerability were measured 
using adverse event (AE) reports, vital signs, electrocardiograms, clin-
ical laboratory measurements and Columbia Suicide Severity Rating 
Scale. Dose proportionality of RTG was assessed by fitting AUC0–inf 
and Cmax to a power model. A point estimate and 90% CI for the 
slope of the regression line obtained by regressing log(PK parameter) 
on log(dose) was calculated. As a secondary analysis, an analysis 
of variance was performed using loge-transformed dose-normalized 
AUC0–inf and Cmax by including periods and treatments as fixed 
effects and subjects as a random effect. All doses were compared with 
the 50 mg reference dose.
Results: Safety: No subject was withdrawn from the study owing to 
AEs and no serious AEs were reported. AEs reported most frequently 
in this population were somnolence, dizziness, and nausea, and the 
incidence of AEs increased with RTG dose. PK: Cmax value increases 
were approximately dose proportional from 50 to 100 mg, but less 
than dose proportional at 200 and 400 mg. AUC0–inf appeared 
to increase more than dose proportionally between 50 mg and the 
higher doses of 100, 200, and 400 mg. This was believed to be due 
to an underprediction of t½ at the 50-mg dose. AUC0–8, which 
represents the dosing interval of RTG with a 3-times-daily dosing 
regimen, was added as a post hoc PK parameter, since this truncated 
AUC is not confounded by determination of t½. AUC0–8 increased 
proportionally across the range of 50 to 400 mg.
Conclusion: Single oral doses of RTG (50–400 mg) were generally 
well tolerated in Taiwanese subjects. The PK parameters for RTG 
and NAMR in the current study in Taiwanese subjects are consistent 
with single-dose PK parameters obtained at these doses in healthy 
Western subjects.
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Introduction: Cachexia decreases CYP3A metabolism of oxycodone, 
while its influence on CYP2D6 metabolism remains to be clarified in 
